Genome & Co. Ltd. has reported preclinical findings of its anti-CNTN4 antibody, GENA-104A16, and anti-APP antibody, 5A7 — stressing the contactin-4 (CNTN4) and amyloid precursor protein (APP) axis as a potential target for immuno-oncology. In the latest murine experiments, investigators led by Genome executives and researchers of Gwangju Institute of Science and Technology (GIST) found that blocking the interaction between CNTN4 and APP promoted cancer-destroying responses in mice, suggesting the pathway as a target for immunotherapy. Read More
Researchers from Zymeworks Inc. presented preclinical data for the novel glypican-3 (GPC3)-targeting antibody-drug conjugate (ADC), ZW-251, being developed as an anticancer agent. Read More
Dewpoint Therapeutics Inc. has nominated its first development candidate, DPTX-3186, an orally administered small-molecule condensate modulator inhibiting the oncogenic function of β-catenin, for the treatment of Wnt-driven cancers. Read More
Researchers at the Stony Brook University Renaissance School of Medicine performed a screening in search of Kruppel-like factor 15 (KLF15) agonists for treating proteinuric injuries in the kidney. Read More
Kivu Bioscience has closed a $92 million series A financing to advance its topoisomerase I inhibitor-based antibody-drug conjugate (ADC) pipeline into the clinic. Read More
Previous reports have disclosed the development of Shigella conjugate vaccines (SCVs) using a platform squaric acid chemistry conjugation approach and carrier protein recombinant fragment of tetanus toxin heavy chain (rTTHc). Read More
Baobab Aibio Co. Ltd. has disclosed transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer. Read More
Lisata Therapeutics Inc. has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab in a preclinical animal model for the treatment of endometriosis. Read More
National Institutes of Pharmaceutical R&D Co. Ltd. has synthesized fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer. Read More
Biocells (Beijing) Biotech Co. Ltd. has identified aquaporin-4 (AQP4) inhibitors reported to be useful for the treatment of cerebral ischemia. Read More
The development of covalent KRAS G12C inhibitors has represented a significant advance for non-small-cell lung cancer treatment, but other mutations such as KRAS G13C/D still lack effective treatments. Read More
Dartmouth College has divulged fatty acid mimetics acting as free fatty acid FFA1 receptor (GPR40) and/or FFA4 receptor (GPR120) agonists reported to be useful for the treatment of obesity and type 2 diabetes. Read More
Scientists at Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, Institut National De La Santé et de la Recherche Médicale, Institut Pasteur de Lille and Université de Lille have patented conjugates comprising siderophore moieties covalently linked to cargo moieties through a linker reported to be useful for the diagnosis and treatment of bacterial infections. Read More
Hematopoietic progenitor kinase 1 (HPK1) is expressed in hematopoietic cells, including T cells, B cells and dendritic cells (DCs). Suppression of HPK1 activity has shown an antitumor effect in preclinical models. Read More
Moma Therapeutics Inc. has reported preclinical results on MOMA-313, a potent and selective DNA polymerase θ (POLθ) inhibitor under development for the treatment of homologous recombinant (HR)-deficient cancers. Read More
